Cynomolgus ALK-1/ACVRL1 Protein

Cat. No. ALK-CM101

KVCJUS

| Description | |
|-------------------------|---|
| Source | Recombinant Cynomolgus ALK-1/ACVRL1 Protein is expressed from HEK293 with His tag at the C-Terminus. |
| | It contains Asp22-GIn118. |
| Accession | XP_005570958.1 |
| Molecular Weight | The protein has a predicted MW of 11.86 kDa. Due to glycosylation, the protein migrates to 25-35 kDa based on Tris-Bis PAGE result. |
| Endotoxin | Less than 1EU per μg by the LAL method. |
| Purity | > 95% as determined by Tris-Bis PAGE |
| | > 95% as determined by HPLC |
| Formulation and Storage | |
| Formulation | Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage | -20 to -80°C for 12 months as supplied from date of receipt20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Background | |
| | Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence. |

Assay Data



SEC-HPLC



Cynomolgus ALK-1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

The purity of Cynomolgus ALK-1 is greater than 95% as determined by SEC-HPLC.